News and blogs
334 results found.
Non-Hodgkin lymphoma drug authorised for use in the UK
A drug for non-Hodgkin lymphoma, epcoritamab, has been authorised for use in the UK for adults.
This MDS World Awareness Day, four people share their story
October 25 every year is World MDS Awareness Day. This year, four people share their story of living with MDS.
Drug, zanubrutinib, now recommended for adults with CLL across the UK
Zanubrutinib has been recommended for adults with the blood cancer, chronic lymphocytic leukaemia (CLL) in England.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
We're calling for UK wide guidance for healthcare staff on masks and testing
As we head into winter, and COVID rates rising, we want to help protect those with blood cancer. We’re calling for UK-wide guidance to be reintroduced asking healthcare staff, to wear masks in clinical settings.
What we can achieve with £1 million
We're proud to announce We’ve invested over £1 million funding five research projects, across five different blood cancers
The story of Dr Jane C Wright, pioneer of blood cancer research
Born in 1919, Dr Wright transformed chemotherapy from an untested, experimental last resort, to a proven, effective blood cancer treatment. Throughout her career Jane overcame prejudice and other barriers to leave a legacy of millions of lives saved.
"Father of the blood bank" - Charles R. Drew's story
For Black History Month, we are celebrating Charles R. Drew who was an African American surgeon and researcher who pioneered in the field of blood transfusions, blood storage and created the first blood banks.
Charity welcomes Liberal Democrats leader’s cancer pledge after he revealed insight into blood cancer experience
Blood Cancer UK have welcomed the Lib Dem leaders cancer pledge after he revealed insight into blood cancer experience.
Myeloma combination therapy approved for use
The combination therapy, DRT, has been approved for use in England and Wales for those with myeloma who are not eligible for a stem cell transplant
Solomon's unexpected multiple myeloma diagnosis
After visiting his GP about a 'barely noticeable' lump on the side of his neck which was found to be benign, Solomon, who felt otherwise fit and well, was shocked to be diagnosed with a rare type of blood cancer – multiple myeloma – in 2018.
Ruxolitinib approved for treatment of polycythaemia vera in England and Wales
The drug, ruxolitinib, has been recommended for use by NICE to treat the blood cancer polycythaemia vera in those whose disease is resistant or intolerant to the treatments hydroxycarbamide/hydroxyurea.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
Clinical trials give a feeling of hope for those living with blood cancer
Rachel contacted the Clinical Trials Support Service to find out whether she could potentially take part in a clinical trial and contribute to blood cancer research.
"The dark times can be overcome by anyone" – David's running epiphany
David Lauder has completed his 19th Great North Run in support of blood cancer research. He's seeking to raise awareness of blood cancer by telling his story – without the jargon – and hopes to demonstrate that the dark times can be overcome by anyone.
Stephen Fry urges people with blood cancer to qualify that their individual condition is a type of blood cancer, to help raise crucial awareness.
76% of people with disease don’t get told they have a type of blood cancer at diagnosis. Neither did Aimee Togher, who was recently diagnosed with Hodgkin’s lymphoma.
Yorkshire Farmhouse raises £1.95 million money for vital blood cancer research!
We’ve just found out that the latest Omaze Million Pound House Draw raised a staggering £1.95m in just six weeks to support vital blood cancer research. Yes, you read that right – £1,950,000!
Winding down of National Cancer Research Institute ‘sad’ for those with blood cancer
Today, the UK's National Cancer Research Institute announced it is winding down. Launched in 2001, only last year, the organisation consulted widely to produce a new strategy. Now board members have made the decision to wind down the Institute.
Blood Cancer UK renews partnership with RareCan to accelerate research into rare cancers
Renewing the partnership will continue to grow RareCan’s patient community, offering more individuals living with a rare blood cancer diagnosis the opportunity to volunteer to take part in clinical research.
Reinvigorating commercial clinical trials in the UK will help us beat blood cancer
The UK Government has recently made some big announcements about commercial clinical trials and life sciences in the UK. This blog explores some of those recommendations, commitments and what they mean for the blood cancer community.
